Cidofovir anhydrous
As of the edition of 20 October 2026, Cidofovir anhydrous is a small molecule: marketed, first approved in 1996 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Vistide
- First approved
- 26 June 1996 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Gilead Sciences
- Withdrawn from market
- 22 August 2014 (in some regions)
- Registered trials
- 27, 4 stopped early
- Disease areas
- Urinary and reproductive; Infections; Immune system; Eye; Pregnancy and women's health; Cancer
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 4 | 0 | 1 |
| Phase 1 | 8 | 6 | 0 | 1 |
| Phase 2 | 9 | 5 | 1 | 2 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 27 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Acquired holder and Lead sponsor of trials | 2003 to now |